Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
0
Canada
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Brl 14151
2. Brl-14151
3. Brl14151
4. Clavulanate
5. Clavulanate, Potassium
6. Clavulanate, Sodium
7. Clavulanic Acid
8. Clavulanic Acid, Monopotassium Salt
9. Clavulanic Acid, Monosodium Salt
10. Mm 14151
11. Mm-14151
12. Mm14151
13. Potassium Clavulanate
14. Potassium, Clavulanate
15. Sodium Clavulanate
1. Potassium Clavulanate
2. 61177-45-5
3. Clavulanic Acid Potassium Salt
4. Brl 14151k
5. Clavulanate (potassium)
6. Q42omw3at8
7. Chebi:85264
8. Brl-14151k
9. Potassium (2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
10. Potassium (z)-(2r,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylate
11. Potassium;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
12. Amonate
13. Potassium (2r,5r,z)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
14. Clavulansaeure Kaliumsalz
15. Einecs 262-640-9
16. Unii-q42omw3at8
17. Potassium Clavlanate
18. Clavulanate Potassium [usan:usp:jan]
19. Chembl1003
20. Schembl203411
21. Clavulanic Acid Potassium
22. Hy-a0256a
23. Dtxsid60210067
24. Hms3715b13
25. Clavulanate Potassium (jp17/usp)
26. Potassium Clavulanate [jan]
27. Bcp13548
28. Clavulanate Potassium [usan]
29. Clavulanate Potassium [vandf]
30. Potassium Clavulanate [mart.]
31. Potassium Clavulanate Cellulose(1:1)
32. Akos015961326
33. Clavulanate Potassium [who-dd]
34. Ccg-221126
35. 4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3-(2-hydroxyethylidene)-7-oxo-, Monopotassium Salt, (2r-(2alpha,3z,5alpha))-
36. Ac-13551
37. Bp-30181
38. Clavulanate Potassium [green Book]
39. Potassium (2r-(2alpha,3z,5alpha))-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylate
40. Clavulanate Potassium [orange Book]
41. Potassium Clavulanate [ep Monograph]
42. Clavulanate Potassium [usp Monograph]
43. Cs-0019771
44. Augmentin Component Clavulanate Potassium
45. C-6660
46. Clavulox Component Clavulanate Potassium
47. D02370
48. D84066
49. Timentin Component Clavulanate Potassium
50. A833076
51. Clavulanate Potassium Component Of Augmentin
52. Clavulanate Potassium Component Of Clavulox
53. Clavulanate Potassium Component Of Timentin
54. Clavulanic Acid (as Clavulanate Potassium)
55. Clavulanic Acid Potassium 100 Microg/ml In Water
56. W-105420
57. Clavulanate Potassium+microcrystalline Cellulose(1:1)
58. Potassium Clavulanate (40%) : Silicon Dioxide Mixture
59. Q27158444
60. Potassium Clavulanate (50%) : Microcrystalline Cellulose
61. Clavulanate Potassium Salt, Antibiotic For Culture Media Use Only
62. Potassium Clavulanate - 1:1 Mixture With Cellulose, Antibiotic For Culture Media Use Only
63. (2r,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2beta-carboxylic Acid Potassium Salt
64. 4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3-(2-hydroxyethylidene)-7-oxo-, Monopotassium Salt, (2r-(2.alpha.,3z,5.alpha.))-
65. Potassium (2r,3z,5r)-3-(2-oxidanylethylidene)-7-oxidanylidene-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
66. Potassium (2r,5r,z)- 3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
67. Potassium(2r,5r,z)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
Molecular Weight | 237.25 g/mol |
---|---|
Molecular Formula | C8H8KNO5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 237.00395384 g/mol |
Monoisotopic Mass | 237.00395384 g/mol |
Topological Polar Surface Area | 89.9 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 329 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-29
Pay. Date : 2014-02-13
DMF Number : 25714
Submission : 2012-01-16
Status : Active
Type : II
Certificate Number : R1-CEP 2011-374 - Rev 00
Issue Date : 2017-12-15
Type : Chemical
Substance Number : 1140
Status : Valid
NDC Package Code : 42677-104
Start Marketing Date : 2007-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.5kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2018-01-16
Registration Number : 20120615-113-F-69-16(1)
Manufacturer Name : Shandong New Time Pharmaceutical Co.,Ltd.
Manufacturer Address : No.1, North Outer Ring Road, Feixian County, Shandong Province, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25718
Submission : 2012-01-16
Status : Active
Type : II
Certificate Number : R1-CEP 2011-375 - Rev 02
Issue Date : 2021-04-08
Type : Chemical
Substance Number : 1653
Status : Valid
NDC Package Code : 42677-104
Start Marketing Date : 2007-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.5kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2018-01-16
Registration Number : 20120615-113-F-69-16(1)
Manufacturer Name : Shandong New Time Pharmaceutical Co.,Ltd.
Manufacturer Address : No.1, North Outer Ring Road, Feixian County, Shandong Province, China
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-09-13
Pay. Date : 2014-02-13
DMF Number : 25719
Submission : 2012-01-16
Status : Active
Type : II
NDC Package Code : 42677-104
Start Marketing Date : 2007-02-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.5kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2018-01-16
Registration Number : 20120615-113-F-69-16(1)
Manufacturer Name : Shandong New Time Pharmaceutical Co.,Ltd.
Manufacturer Address : No.1, North Outer Ring Road, Feixian County, Shandong Province, China
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-06
Pay. Date : 2014-03-31
DMF Number : 27903
Submission : 2014-02-05
Status : Active
Type : II
Certificate Number : R1-CEP 2014-329 - Rev 00
Issue Date : 2021-03-03
Type : Chemical
Substance Number : 1653
Status : Valid
NDC Package Code : 55657-105
Start Marketing Date : 2006-02-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/2kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2014-10-10
Registration Number : 20141010-113-F-78-23
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd.
Manufacturer Address : Pharmaceutical Industrial Park, Economic & Technological Development Zone, Datong, Shanxi, China
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-09-08
Pay. Date : 2014-03-31
DMF Number : 27966
Submission : 2014-03-12
Status : Active
Type : II
Certificate Number : R1-CEP 2014-320 - Rev 00
Issue Date : 2021-03-05
Type : Chemical
Substance Number : 1140
Status : Valid
NDC Package Code : 55657-105
Start Marketing Date : 2006-02-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/2kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2014-10-10
Registration Number : 20141010-113-F-78-23
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd.
Manufacturer Address : Pharmaceutical Industrial Park, Economic & Technological Development Zone, Datong, Shanxi, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15211
Submission : 2000-12-26
Status : Active
Type : II
Certificate Number : R1-CEP 2003-262 - Rev 03
Issue Date : 2020-06-17
Type : Chemical
Substance Number : 1140
Status : Valid
NDC Package Code : 48866-9981
Start Marketing Date : 2022-11-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2022-04-25
Registration Number : 20220425-113-F-96-26
Manufacturer Name : Lek farmacevtska družba dd, Poslovna enota Proizvodnja Lendava
Manufacturer Address : Trimlini 2D, Lendava, 9220, Slovenia
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-10-24
Pay. Date : 2018-05-17
DMF Number : 32777
Submission : 2018-05-17
Status : Active
Type : II
Certificate Number : R1-CEP 2004-241 - Rev 03
Issue Date : 2020-02-07
Type : Chemical
Substance Number : 1653
Status : Valid
NDC Package Code : 48866-9981
Start Marketing Date : 2022-11-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2022-04-25
Registration Number : 20220425-113-F-96-26
Manufacturer Name : Lek farmacevtska družba dd, Poslovna enota Proizvodnja Lendava
Manufacturer Address : Trimlini 2D, Lendava, 9220, Slovenia
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Clavulanate Potassium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clavulanate Potassium, including repackagers and relabelers. The FDA regulates Clavulanate Potassium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clavulanate Potassium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clavulanate Potassium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clavulanate Potassium supplier is an individual or a company that provides Clavulanate Potassium active pharmaceutical ingredient (API) or Clavulanate Potassium finished formulations upon request. The Clavulanate Potassium suppliers may include Clavulanate Potassium API manufacturers, exporters, distributors and traders.
click here to find a list of Clavulanate Potassium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Clavulanate Potassium DMF (Drug Master File) is a document detailing the whole manufacturing process of Clavulanate Potassium active pharmaceutical ingredient (API) in detail. Different forms of Clavulanate Potassium DMFs exist exist since differing nations have different regulations, such as Clavulanate Potassium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Clavulanate Potassium DMF submitted to regulatory agencies in the US is known as a USDMF. Clavulanate Potassium USDMF includes data on Clavulanate Potassium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Clavulanate Potassium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Clavulanate Potassium suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Clavulanate Potassium Drug Master File in Korea (Clavulanate Potassium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Clavulanate Potassium. The MFDS reviews the Clavulanate Potassium KDMF as part of the drug registration process and uses the information provided in the Clavulanate Potassium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Clavulanate Potassium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Clavulanate Potassium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Clavulanate Potassium suppliers with KDMF on PharmaCompass.
A Clavulanate Potassium CEP of the European Pharmacopoeia monograph is often referred to as a Clavulanate Potassium Certificate of Suitability (COS). The purpose of a Clavulanate Potassium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clavulanate Potassium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clavulanate Potassium to their clients by showing that a Clavulanate Potassium CEP has been issued for it. The manufacturer submits a Clavulanate Potassium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clavulanate Potassium CEP holder for the record. Additionally, the data presented in the Clavulanate Potassium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clavulanate Potassium DMF.
A Clavulanate Potassium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clavulanate Potassium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Clavulanate Potassium suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Clavulanate Potassium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Clavulanate Potassium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Clavulanate Potassium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Clavulanate Potassium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Clavulanate Potassium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Clavulanate Potassium suppliers with NDC on PharmaCompass.
Clavulanate Potassium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clavulanate Potassium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clavulanate Potassium GMP manufacturer or Clavulanate Potassium GMP API supplier for your needs.
A Clavulanate Potassium CoA (Certificate of Analysis) is a formal document that attests to Clavulanate Potassium's compliance with Clavulanate Potassium specifications and serves as a tool for batch-level quality control.
Clavulanate Potassium CoA mostly includes findings from lab analyses of a specific batch. For each Clavulanate Potassium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clavulanate Potassium may be tested according to a variety of international standards, such as European Pharmacopoeia (Clavulanate Potassium EP), Clavulanate Potassium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clavulanate Potassium USP).
LOOKING FOR A SUPPLIER?